Pancreatoblastoma

Pancreatoblastoma is a rare malignant epithelial neoplasm of the pancreas, typical of childhood, characterized by a combination of acinar-like, ductal and sometimes endocrine differentiation and a distinctive histologic appearance with squamoid nests (or morules), which are a highly valuable diagnostic clue. Among pancreatic neoplasms of childhood, it represents one of the main malignant forms, whereas in adults it is exceptional and often difficult to diagnose because of morphologic variability and radiologic overlap with other solid pancreatic masses.

Clinically, the tumor frequently presents as a large abdominal mass, sometimes associated with pain, weight loss or compressive signs. A subset of patients has increased alpha-fetoprotein (AFP), a useful supportive and monitoring marker that is neither constant nor specific. Diagnosis requires an integrated pathway based on imaging (ultrasonography, CT and MRI), adequate histologic sampling and immunohistochemical panels directed at demonstrating acinar differentiation and identifying squamoid nests, which are often associated with nuclear beta-catenin accumulation.

Treatment is typically multimodal. Complete surgical resection (R0) is the primary objective and the most robust prognostic determinant; in initially unresectable cases, neoadjuvant chemotherapy may permit conversion to surgery. Management should be centralized within multidisciplinary teams experienced in pediatric oncology and pancreatic surgery because the rarity of the disease and its frequent presentation as a large mass require highly individualized technical and oncologic decisions, including strategies to reduce surgical morbidity and preserve pancreatic function whenever possible.

The epidemiology of pancreatoblastoma is dominated by its rarity. Incidence is low, and most evidence comes from pediatric registries, multicenter series and retrospective analyses, resulting in variable estimates and substantial heterogeneity in reported diagnostic and therapeutic pathways. The tumor arises mainly during the first years of life, with a concentration in preschool age, but may also occur in older children and, rarely, adolescents and adults.

Sex distribution in pediatric series is inconsistent across studies, partly because of small numbers; in clinical practice, no demographic profile is sufficiently discriminatory to guide diagnosis. The tumor may involve the pancreatic head, body or tail. Masses can become very large before causing symptoms because the retroperitoneal pancreas provides considerable space for growth and early symptoms are often subtle.

The etiologic causes of pancreatoblastoma are undefined, and no exposure has been documented as a necessary and sufficient direct cause. In the absence of a demonstrated etiology, the literature identifies genetic-syndromic risk factors and predisposing conditions in which the tumor is observed more frequently than in the general population, suggesting a role for dysregulation of imprinting and embryonic pancreatic-development pathways.

Among the most relevant associations, Beckwith-Wiedemann syndrome and abnormalities of the 11p15 imprinting region represent a recognized risk context for embryonal tumors, including hepatoblastoma and Wilms tumor and, in some reports, pancreatoblastoma. Another reported association is familial adenomatous polyposis, consistent with involvement of the APC/beta-catenin pathway in a subset of cases. These conditions do not explain most pancreatoblastomas, which remain sporadic, but they are clinically important because they affect surveillance, counseling and diagnostic vigilance when compatible signs or symptoms are present.

In summary, pancreatoblastoma is a rare embryonal pancreatic tumor typical of childhood. Its etiology remains undefined, whereas the principal documented risk factors concern syndromic settings related to imprinting abnormalities at 11p15 and, more rarely, APC-related predisposition.

For pancreatoblastoma, there are no population screening programs because incidence is too low to support a generalized approach and no noninvasive test has sufficient accuracy. Early detection in the general population therefore depends on recognizing clinical signs that warrant abdominal imaging, usually beginning with ultrasonography.

A separate issue concerns children with Beckwith-Wiedemann syndrome or 11p15 abnormalities. In these settings, oncologic surveillance is already recommended for more common embryonal tumors, and periodic abdominal ultrasonography with AFP monitoring is used for early detection, particularly of hepatoblastoma. Although not dedicated surveillance for pancreatoblastoma, the same follow-up infrastructure may facilitate incidental recognition of pancreatic masses at a less advanced stage, potentially improving resectability.

In individuals with familial adenomatous polyposis, no universally standardized protocol exists for pancreatic surveillance aimed at pancreatoblastoma because the event remains exceptional. Knowledge of the association with the APC/beta-catenin pathway nevertheless increases clinical vigilance in the presence of persistent abdominal symptoms or suspicious ultrasonographic findings.

Overall, reasonable surveillance is risk-adapted: absent in the general population, structured in syndromic settings already subject to embryonal-tumor screening protocols, and guided by symptoms or incidental findings in other cases.

Pancreatoblastoma is considered an embryonal tumor of the pancreas that reproduces morphologic and molecular aspects of fetal pancreatic development. Pathogenesis is closely linked to signaling pathways involved in epithelial development and differentiation, with a central role for the WNT/beta-catenin pathway and, in many series, imprinting abnormalities involving 11p, consistent with the biology of childhood embryonal tumors.

At the genomic level, pancreatoblastomas harbor alterations involving APC and/or CTNNB1, leading to nuclear beta-catenin accumulation, particularly within squamoid nests. This finding is relevant both to tumor biology and diagnosis, because nuclear beta-catenin positivity in specific tumor components can substantially guide the differential diagnosis. In adult cases, rarity makes molecular profiling more commonly useful to clarify diagnosis and occasionally identify possible targets, although no standard targets comparable to those in other pancreatic neoplasms have been established.

Recurring biological features of clinical relevance

• Frequent involvement of the WNT/beta-catenin pathway with nuclear beta-catenin accumulation, often accentuated in squamoid nests.
• Chromosomal-region and imprinting abnormalities, including 11p abnormalities, biologically linking the tumor to childhood embryonal neoplasms.
• A molecular profile generally distinct from pancreatic ductal adenocarcinoma, with less emphasis on the classic driver mutations of adulthood.

Histologically, pancreatoblastoma is characterized by lobulated growth with areas showing acinar-like differentiation, sometimes with acinus-like structures and pancreatic enzyme production, a variable ductal component and, in some cases, neuroendocrine elements. The most suggestive finding is squamoid nests, often without marked atypia and not necessarily highly proliferative, but highly useful as a morphologic signature. Necrosis, mitotic activity and vascular invasion vary among cases and contribute to risk stratification, especially when integrated with tumor size, resectability and metastatic disease.

Immunohistochemically, expression of acinar enzymes such as trypsin and chymotrypsin supports acinar differentiation; nuclear beta-catenin in morules and epithelial markers complete the profile. Immunophenotyping also helps distinguish pancreatoblastoma from pediatric neoplasms that may mimic it, including solid pseudopapillary neoplasm, neuroendocrine tumors and acinar cell carcinomas, as well as sarcomas and lymphomas in the clinical differential diagnosis.

Supportive immunophenotype and differential diagnosis

• Expression of acinar differentiation markers (trypsin, chymotrypsin and lipase) supporting the acinar-like component.
• Beta-catenin with nuclear accumulation, particularly in squamoid nests, as a highly suggestive feature in the appropriate morphologic context.
• Targeted panels to exclude solid pseudopapillary neoplasm, neuroendocrine neoplasms and other rare epithelial pancreatic neoplasms of childhood.

Overall, pancreatoblastoma is biologically a developmental tumor, with morphologic and molecular signatures that, when recognized, permit more rapid diagnosis and more appropriate treatment planning, particularly when preoperative sampling is limited.

The clinical manifestations of pancreatoblastoma are often nonspecific and depend mainly on tumor size and location. Many patients present with a palpable abdominal mass, persistent abdominal pain or distension, sometimes associated with loss of appetite and weight loss. Retroperitoneal growth may allow the tumor to become large before producing severe symptoms, favoring delayed diagnosis.

When the neoplasm involves the pancreatic head or compresses the bile ducts, jaundice, dark urine and pruritus may occur, although this presentation is less typical than in adult ductal tumors. Compression of the duodenum or stomach may cause nausea, vomiting and early satiety. With vascular invasion or marked local extension, pain may become continuous and interfere with eating and sleep quality.

A subset of patients has increased AFP, which may emerge during laboratory assessment of a pediatric abdominal mass. AFP is not a diagnostic criterion, but it may support suspicion of an embryonal tumor and provide a useful dynamic marker for monitoring response, residual disease and recurrence when elevated at diagnosis.

Clinical presentations that most often lead to abdominal imaging

• A palpable abdominal mass or progressive increase in abdominal circumference.
• Persistent abdominal pain, sometimes associated with loss of appetite and weight loss.
• Recurrent nausea and vomiting from duodenal or gastric compression.
• Obstructive jaundice in tumors of the pancreatic head with biliary compression.
• Nonspecific laboratory abnormalities or increased AFP in the setting of a pediatric abdominal mass.

Physical examination may reveal, in addition to a palpable mass, signs of malnutrition, abdominal tenderness and, in advanced cases, hepatomegaly or findings related to liver metastases. The clinical picture alone cannot reliably distinguish pancreatoblastoma from other pediatric pancreatic masses, making a structured diagnostic pathway necessary.

Diagnostic suspicion generally arises from detection of an abdominal mass in a child or persistent symptoms warranting imaging. The rational sequence of investigations aims to define location and resectability, obtain a reliable histologic diagnosis and complete staging with particular attention to the liver and regional lymph nodes.

First-line assessment includes abdominal ultrasonography, often the initial examination because it is readily available and avoids radiation. Ultrasonography may demonstrate a heterogeneous solid pancreatic mass and guide second-line imaging. CT and MRI are fundamental for defining local extension, relationships with mesenteric and splenic vessels, duodenal involvement, possible vascular invasion and metastases, especially in the liver. MRI offers advantages for tissue characterization and biliary assessment, whereas CT is often decisive for preoperative anatomic mapping.

Laboratory tests include complete blood count, hepatic and pancreatic profiles, inflammatory indices and selected tumor markers. AFP, when elevated, is useful both diagnostically and as a baseline for follow-up, but a normal value does not exclude the tumor. Endocrine and glycemic assessment may be useful at baseline, especially when pancreatic resection with potential metabolic consequences is anticipated.

Definitive diagnosis requires histology. In many pediatric cases, the choice between preoperative biopsy and primary surgery depends on resectability. If the tumor appears resectable with reasonable margins and acceptable surgical risk, an upfront surgical approach may be used; in locally advanced or apparently unresectable disease, biopsy becomes crucial to initiate neoadjuvant chemotherapy. Sampling may be obtained percutaneously under imaging guidance or, in selected cases, by endoscopic ultrasonography with fine-needle aspiration, considering the need for sufficient material to assess architecture, immunohistochemistry and, when indicated, molecular features.

According to pediatric-oncology consensus recommendations for rare tumors, diagnostic attribution should rest on integrated morphology and immunohistochemistry, with expert-center review whenever possible. A diagnosis of pancreatoblastoma requires coherent clinical-pathologic features and exclusion of differential diagnoses using appropriate panels:

Essential elements for a reliable diagnosis

• A pancreatic mass defined by imaging, with assessment of vascular relationships and the liver.
• Histologic confirmation with compatible architecture and identification of squamoid nests in the appropriate context.
• Immunohistochemical support for acinar differentiation and a consistent pattern, including beta-catenin in characteristic regions when useful.
• Targeted exclusion of the principal alternatives: solid pseudopapillary neoplasm, acinar cell carcinoma, neuroendocrine tumors and other rare pediatric neoplasms.
• Completion of staging with chest and abdominal imaging and dedicated assessment of the liver for metastases.

Diagnostic completion includes surgical resectability assessment and early multidisciplinary review. In suspected syndromic settings, genetic counseling and targeted testing, for example for Beckwith-Wiedemann syndrome or familial adenomatous polyposis, are appropriate because the information may affect surveillance and family management as well as biological understanding of the case.

In summary, diagnosis proceeds from first- and second-line imaging, laboratory evaluation with AFP as a supportive marker when elevated, histologic confirmation with immunohistochemistry and completion of staging with attention to the liver and lymph nodes, culminating in a shared definition of resectability and multimodal strategy.

Staging of pancreatoblastoma has no single universally adopted tumor-specific system because its rarity and differences between pediatric and adult populations have historically limited standardization. In practice, assessment of extent is based on three high-impact decision axes: localized versus metastatic disease, nodal or vascular involvement and, above all, resectability. This approach permits clear communication and guides the choice between upfront surgery and neoadjuvant treatment.

Preoperative assessment should describe in detail tumor size and location, relationships with the superior mesenteric artery, portal vein and superior mesenteric vein, possible invasion of the spleen or duodenum and the presence of liver metastases. The liver is the most relevant metastatic site and critically affects prognosis and strategy, including possible combined resection or sequential approaches at high-expertise centers.

Practical assessment of disease extent in pancreatoblastoma

• Localized resectable disease: tumor confined to the pancreas without metastases, with vascular relationships compatible with complete first-intent resection (R0).
• Locally advanced disease: no metastases, but vascular involvement or local extension that reduces the likelihood of upfront R0 resection, frequently indicating neoadjuvant chemotherapy and reassessment.
• Metastatic disease: distant metastases, most often involving the liver, with an individualized multimodal strategy integrating chemotherapy and, in selected cases, surgical or locoregional procedures.

Prognosis is closely related to achieving complete resection and the absence of metastases at diagnosis. In patients who achieve R0 resection, the probability of disease control improves substantially, although recurrence remains possible and requires close follow-up. Other prognostic factors include tumor size, vascular invasion, response to chemotherapy when used, nodal involvement and the AFP trend when elevated at presentation.

In the rare adult cases, reported outcomes are often poorer than in pediatric patients, probably because of later diagnosis, larger tumors at presentation and difficulties in preoperative classification and treatment planning, as well as incompletely understood biological differences. At every age, centralization and shared strategies among oncology, surgery, radiology and pathology are decisive for optimizing prognosis and quality of care.

Treatment of pancreatoblastoma is typically multimodal. Surgery with curative intent is the cornerstone and the most important determinant of outcome; chemotherapy is used as neoadjuvant and/or adjuvant support according to resectability, metastatic disease and recurrence risk. Because of the tumor’s rarity, management is based on consensus recommendations and pediatric series, adapted case by case and requiring multidisciplinary decisions.

In resectable localized disease, the objective is complete resection (R0). The procedure depends on location: pancreaticoduodenectomy for lesions of the head, distal pancreatectomy for body-tail lesions, and selected central resections at experienced centers when functional preservation is realistic without compromising oncologic radicality. Regional lymphadenectomy is often performed concurrently for staging and local control, particularly when imaging or intraoperative findings suggest nodal involvement.

In locally advanced disease, neoadjuvant chemotherapy is frequently used to reduce tumor volume and increase the likelihood of R0 resection, followed by radiologic reassessment. Regimens based on cisplatin and doxorubicin are among the most frequently used in pediatric series, with variants and intensification for suboptimal response or recurrence, while balancing efficacy and toxicity. Response should be assessed by serial imaging and, when applicable, AFP kinetics.

In metastatic disease, systemic chemotherapy is the initial foundation. In selected subgroups with a good response and potentially controllable liver metastases, an integrated approach including surgery for the primary tumor and locoregional or surgical management of metastases may be considered at highly specialized centers. Radiotherapy is generally not a standard cornerstone but may be discussed in selected settings for local control or palliation, with particular caution in children because of late effects.

Treatment objectives according to the clinical setting

• Resectability and R0: the absolute priority, using an upfront strategy when feasible or after neoadjuvant therapy when necessary.
• Reduction of recurrence risk: perioperative chemotherapy according to pediatric protocols and recommendations for rare tumors.
• Control of metastatic disease: systemic treatment with reassessment for selected surgical or locoregional approaches.
• Functional preservation: minimizing endocrine and exocrine insufficiency when compatible with oncologic radicality.

Management of complications and general condition is an integral part of treatment. Large masses may require nutritional support, structured analgesia and thromboembolic prophylaxis according to risk. In operated patients, prevention and treatment of pancreatic fistula, delayed gastric emptying and infections directly affect the ability to complete systemic therapy and therefore oncologic outcome.

Follow-up after treatment for pancreatoblastoma should be planned and close during the first years, when recurrence risk is highest, although follow-up schedules are not universally identical across centers. Surveillance integrates clinical assessment, periodic imaging and laboratory monitoring directed both at disease and late treatment effects.

If AFP was elevated at diagnosis, serial monitoring is useful as a dynamic indicator of response and possible recurrence, always interpreted together with imaging. Follow-up imaging uses ultrasonography, CT or MRI according to age, risk, postoperative findings and the need to reduce radiation exposure, with particular attention to the liver and pancreatic bed.

A central component of follow-up is assessment of pancreatic function. After extensive resections, the risk of exocrine pancreatic insufficiency and glycemic abnormalities increases and may emerge over time; surveillance therefore includes symptoms of malabsorption, weight trends, vitamin status when indicated and metabolic monitoring. In patients treated with anthracyclines or platinum, follow-up should also include monitoring for potential late cardiac, renal and auditory toxicities according to established pediatric protocols.

In summary, follow-up combines surveillance for recurrence with long-term care focused on growth, nutrition, pancreatic function and late toxicities, coordinated among pediatric oncology, surgery, gastroenterology and clinical nutrition.

Long-term quality-of-life considerations in pancreatoblastoma depend on the interaction among surgical outcomes, chemotherapy effects and the psychological impact of a cancer diagnosis in childhood. Among survivors, quality of life is often affected by the need for prolonged surveillance and possible metabolic and digestive sequelae, with consequences for diet, physical activity and participation in school or work.

After pancreatic resection, dietary adaptation may require time and continuing dietetic support. Exocrine insufficiency, when present, affects weight, body composition and energy levels; pancreatic enzyme replacement and management of micronutrient deficiencies become critical for daily well-being and growth. Glycemic abnormalities may also emerge, requiring therapeutic education and sometimes diabetology care.

Chemotherapy may leave late effects that influence physical performance and perceived health, including persistent fatigue and psychological vulnerability. In pediatric patients, the family dimension is central: long-term management benefits from well-organized transition pathways to adult services when appropriate, ensuring continuity in monitoring sequelae and providing health education.

Psycho-oncologic support and clear communication about the reasons for follow-up, warning signs and strategies for preventing sequelae help reduce fear of recurrence and improve adherence. Overall, quality of life is optimized when oncologic surveillance is integrated with clinical nutrition, rehabilitation, attention to late effects and psychological support.

Complications of pancreatoblastoma may arise from the tumor mass, progression and treatment. Locally, large masses may cause duodenal compression with vomiting and dehydration, biliary compression with jaundice, persistent pain and, more rarely, intratumoral hemorrhage or necrosis with acute clinical deterioration. Invasion of or adherence to major vascular structures increases surgical complexity and the risk of incomplete resection, affecting prognosis.

Dissemination, especially to the liver, may lead to organ failure and general deterioration. Even without metastases, cachexia and malnutrition may develop in patients with prolonged symptoms or functional obstruction, reducing treatment tolerance and slowing postoperative recovery.

Surgical complications include pancreatic fistula, abdominal infections, delayed gastric emptying and hemorrhagic complications. In the long term, resections may cause exocrine pancreatic insufficiency and endocrine abnormalities with diabetes, substantially affecting quality of life and requiring dedicated follow-up.

• Platinum- and anthracycline-related toxicity: nephrotoxicity, ototoxicity, myelosuppression and risk of cumulative cardiotoxicity, requiring structured monitoring.
• Metabolic and nutritional complications: exocrine pancreatic insufficiency, vitamin deficiencies, weight loss and glycemic abnormalities up to post-resection diabetes.
• Recurrence and progression: local or metastatic recurrence requiring integrated salvage strategies and symptomatic support.

Prevention and management of complications require early nutritional optimization, surgery at experienced centers, rigorous toxicity monitoring and long-term multidisciplinary care, with particular attention to late effects in children.